 |
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$25 → $32 |
|
| 30-Jan-13 | Reiterated |
UBS |
Buy |
$29 → $31 |
|
| 30-Jan-13 | Reiterated |
Argus |
Buy |
$28 → $32 |
|
| 22-Jan-13 | Reiterated |
Barclays |
Equal Weight |
$24 → $25 |
|
| 27-Nov-12 | Downgrade |
MKM Partners |
Buy → Neutral |
$29 → $25 |
|
| 05-Oct-12 | Reiterated |
MKM Partners |
Buy |
$27 → $29 |
|
| 01-Nov-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 07-Oct-11 | Initiated |
MKM Partners |
Buy |
$20.50 |
|
| 14-Sep-11 | Downgrade |
Barclays Capital |
Overweight → Equal Weight |
$21 → $19 |
|
| 10-Aug-11 | Upgrade |
Argus |
Hold → Buy |
$21 |
|
| 05-Aug-11 | Upgrade |
Standpoint Research |
Hold → Buy |
$21 |
|
| 14-Mar-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 03-Nov-10 | Downgrade |
Argus |
Buy → Hold |
|
|
| 21-May-10 | Initiated |
Jefferies |
Buy |
$17.80 |
|
| 16-Dec-09 | Initiated |
UBS |
Buy |
|
|
| 27-Apr-09 | Initiated |
Standpoint Research |
Buy |
$20 |
|
| 12-Feb-09 | Upgrade |
Leerink Swann |
Mkt Perform → Outperform |
|
|
| 09-Feb-09 | Upgrade |
UBS |
Neutral → Buy |
|
|
| 02-Feb-09 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
| 28-Jan-09 | Reiterated |
Argus |
Buy |
$20 → $19 |
|
|
|
| 19-Jun-13 06:05PM | Final Glance: Pharmaceuticals companies AP |
| 05:41PM | When Seeking Dividend Payers, Look For Stable Earnings History Investor's Business Daily |
| 05:25PM | CORRECTING and REPLACING Pfizer Announces Final Exchange Ratio of 0.9898 for Zoetis Exchange Offer and Automatic Extension of Offer to Midnight on Friday, June 21, 2013 Business Wire |
| 05:11PM | Sustainable healthcare: trends urge need to put prevention before cure at Financial Times |
| 04:54PM | Pfizer Share Swap for Animal Health Stake Hits Top Limit at Bloomberg |
| 04:30PM | InPlay: Pfizer announces final exchange ratio of 0.9898 for Zoetis (ZTS) exchange offer and automatic extension of offer to midnight on Friday, June 21, 2013 Briefing.com |
| 04:28PM | Pfizer Announces Final Exchange Ratio of 0.9898 for Zoetis Exchange Offer and Automatic Extension of Offer to Midnight on Friday, June 21, 2013 Business Wire |
| 01:49PM | Alcatel-Lucent Sheds Units & Jobs and 2 Other Hot Stocks To Watch at Wall St. Cheat Sheet |
| 01:20PM | Most active New York Stock Exchange-traded stocks AP |
| 01:20PM | Midday Glance: Pharmaceuticals companies AP |
| 01:03PM | 5 Drugs Stocks Driving The Industry Higher at TheStreet |
| 11:22AM | Amarin: FDA Panel Date, Misplaced Hype For Fixed-Dose Combo at TheStreet |
| 10:33AM | Early Glance: Pharmaceuticals companies AP |
| 09:13AM | Amgen In Focus at Seeking Alpha |
| 09:04AM | Will a New Acquisition Send Johnson & Johnson Prices Higher? at Wall St. Cheat Sheet |
| 07:44AM | Protalix signs supply deal with Brazilian govt AP |
| 07:41AM | Pfizer holders should consider Zoetis exchange, says BMO Capital theflyonthewall.com |
| 06:31AM | [video] Time to Get Out of Stocks That Act Like Bonds? at CNBC |
| 18-Jun-13 06:02PM | Final Glance: Pharmaceuticals companies AP |
| 06:01PM | Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel at Bloomberg |
| 05:23PM | Zoetis Exchange Offer Update at Seeking Alpha |
| 04:30PM | "Pay-For Delay" Was Fun While It Lasted at Motley Fool |
| 03:30PM | Ariad's Iclusig in GIST Phase II Study Zacks |
| 02:05PM | What Do These Factors Suggest About Elan Stock? at Wall St. Cheat Sheet |
| 01:18PM | Midday Glance: Pharmaceuticals companies AP |
| 12:26PM | Top Treatments for High Cholesterol at Motley Fool |
| 12:16PM | The NIH Aims To Develop Drugs That Big Pharma Discarded at Forbes |
| 10:21AM | Early Glance: Pharmaceuticals companies AP |
| 10:13AM | Supreme Court Permits Antitrust Scrutiny Of Pharma Settlements at Forbes |
| 07:46AM | Big Pharma's Intellectual Property Blues at Motley Fool |
| 17-Jun-13 11:56PM | Court appoints lead plaintiff in shareholder lawsuit against SAC Reuters |
| 06:04PM | Final Glance: Pharmaceuticals companies AP |
| 04:12PM | Abbott Loves Abbott Laboratories Stock at Motley Fool |
| 03:46PM | Pfizer Sues to Block Generic AzaSite Sales and 2 More Heavily Traded Stocks to Follow at Wall St. Cheat Sheet |
| 03:45PM | Successor To Humira? AbbVie And Galapagos Work On It at Seeking Alpha |
| 03:45PM | Successor To Humira? Abbvie And Galapagos Work On It at Seeking Alpha |
| 01:57PM | American Generics Can't Touch This $8 Billion Drug (Yet) at Motley Fool |
| 01:30PM | Midday Glance: Pharmaceuticals companies AP |
| 01:10PM | Markets Rally on Hope of Continued Fed Stimulus at Motley Fool |
| 12:56PM | Datawatch buying Panopticon in $31.4M stock deal AP |
| 12:38PM | Merck, Pfizer Sue Mylan to Block Proposed Copy of AzaSite at Bloomberg |
| 11:13AM | J&J: Adding Another Pearl to its Acquisition Necklace at Wall St. Cheat Sheet |
| 10:47AM | Huge Upside on Pipeline Strength at Motley Fool |
| 10:47AM | Where Do Your Chicken McNuggets Come From? at Bloomberg |
| 10:43AM | Pfizer: Renal Cancer Treatment Sutent Sales Forecast at Seeking Alpha |
| 10:29AM | Shorts Are Piling Into These Stocks. Should You Be Worried? at Motley Fool |
| 10:29AM | Early Glance: Pharmaceuticals companies AP |
| 08:08AM | BCG Weighs In On First-In-Class Vs. Best-In-Class Drugs -- How Valuable Is Their Advice? at Forbes |
| 08:00AM | Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals PR Newswire |
| 16-Jun-13 07:01PM | UK scientists win funding for new kind of anticoagulant drug at Reuters |
| 06:44PM | Did This Study Just Change the Game for Alzheimer's? at Motley Fool |
| 06:00PM | McDonalds Fisherman Jostles With Kermit to Woo Smartphone Users at Bloomberg |
| 02:05PM | The Top 5 Diseases Caused by Obesity at Motley Fool |
| 15-Jun-13 05:28PM | 3 Winners and 2 Losers From Rigel's Failure at Motley Fool |
| 05:02PM | Last Week's Worst-Performing Dow Components at Motley Fool |
| 02:28PM | Pfizer For Zoetis: The Exchange, Market Mechanics & Analysis at Seeking Alpha |
| 01:24PM | The Dow's Top 3 Stocks From Last Week at Motley Fool |
| 01:09PM | The Dow's Top 3 Stocks This Week at Motley Fool |
| 11:16AM | This Is the Leading Cause of Preventable Hospital Patient Deaths at Motley Fool |
| 14-Jun-13 08:03PM | These Stocks Overcame the Dow's Triple-Digit Drop at Motley Fool |
| 06:41PM | Johnson & Johnson's Gut Feeling About the Future of Medicine at Motley Fool |
| 06:05PM | Pfizer spin-off Zoetis to join S&P 500 AP |
| 06:04PM | Final Glance: Pharmaceuticals companies AP |
| 06:00PM | [video] Who's Afraid of the Fed? Not Cramer at CNBC |
| 05:44PM | Zoetis Set to Join S&P 500; First Horizon National to Join S&P MidCap 400; QLogic to Join S&P SmallCap 600 PR Newswire |
| 04:29PM | Big Pharma's Biggest Opportunity at Motley Fool |
| 02:34PM | Consumers Inflict a Painful Ending to the Dow's Erratic Week at Motley Fool |
| 01:28PM | Midday Glance: Pharmaceuticals companies AP |
| 12:53PM | Strong Product Pipelines Have Pharmaceutical Companies Poised for Growth at Motley Fool |
| 11:00AM | Apremilast Data Presented by Celgene Zacks |
| 11:00AM | These 2 Health Care Stocks Could Win Big With FDA's New 'Breakthrough' Status StreetAuthority Network |
| 10:38AM | Early Glance: Pharmaceuticals companies AP |
| 10:30AM | Lilly Alzheimer's Study Terminated Zacks |
| 09:48AM | Penny-Wise, Pound-Foolish Stem Cell Stocks at Seeking Alpha |
| 07:43AM | Bankers-Turned-CEOs Fight for Elan in Years Biggest Hostile Bid at Bloomberg |
| 05:26AM | Pharma Majors: 2 To Buy, 1 To Avoid And 1 To Sell at Seeking Alpha |
| 13-Jun-13 10:00PM | Dow Jumps On Employment, Retail Data at Motley Fool |
| 08:04PM | Falling World Markets Dont Affect the Dow Today at Motley Fool |
| 06:16PM | Dow Jumps 180 Points, Led by Caterpillar Stock at Motley Fool |
| 06:04PM | Final Glance: Pharmaceuticals companies AP |
| 05:40PM | $2.15B Settlement for Pfizer's Protonix Zacks |
| 05:26PM | 5 Biotech Giants with Lucrative Dividend Yields at Motley Fool |
| 05:18PM | Lilly Stops Trial of Experimental Alzheimers Drug at Bloomberg |
| 05:04PM | Hair-Loss Drugs' Big Growth in China at BusinessWeek |
| 05:00PM | Pfizer Inc (PFE): Today's Featured Drugs Winner at TheStreet |
| 04:46PM | Clearwire Board Likes New DISH Offer and 2 More Heavily Traded Stocks to Follow at Wall St. Cheat Sheet |
| 04:25PM | Is Merck the Best Option In This Group? at Wall St. Cheat Sheet |
| 02:18PM | Billionaire Paul Tudor Jones' Latest Additions at Motley Fool |
| 02:16PM | Is Chinas Healthcare System Causing Problems for GlaxoSmithKline? at Wall St. Cheat Sheet |
| 01:53PM | Why the Pfizer-Teva Settlement Affects the Whole Industy at Motley Fool |
| 01:52PM | Pfizers Two New Top Pills Selling Slower Than Expected at Bloomberg |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 12:46PM | Rise in Alzheimers Patients Creates Health-Care Plays Big Data Download |
| 12:00PM | Dow Today: Pfizer (PFE) Higher at TheStreet |
| 11:28AM | HD Supply may raise up to $1.3 billion in IPO AP |
| 11:10AM | Is Concentration Better Than Diversification in Pharma? at Motley Fool |
| 10:50AM | Teva CFO Discusses Growth Outlook, Acquisitions at Bloomberg |
| 10:22AM | Early Glance: Pharmaceuticals companies AP |
| 09:37AM | 2 Healthcare Companies With Recent Intensive Insider Selling at Seeking Alpha |
| 08:16AM | [video] It's Raining Yen, Stocks Soaked at TheStreet |
|
|
| Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SCHULMAN AMY W | Executive Vice President | May 15 | Sale | 29.36 | 70,000 | 2,055,389 | 223,497 | May 16 08:18 PM | | READ IAN C | Chairman & CEO | May 15 | Sale | 29.39 | 69,900 | 2,054,335 | 1,061,463 | May 16 08:10 PM | | DAMELIO FRANK A | Executive Vice President | May 15 | Sale | 29.33 | 100,000 | 2,932,863 | 485,682 | May 16 07:24 PM | | Germano Geno J | Business Unit President | Mar 14 | Sale | 28.00 | 40,000 | 1,120,000 | 224,392 | Mar 14 05:54 PM | | LANKLER DOUGLAS M | Executive Vice President | Mar 13 | Sale | 28.00 | 15,000 | 420,060 | 88,523 | Mar 14 05:52 PM | | MADDALUNA ANTHONY J | Executive Vice President | Mar 08 | Sale | 28.15 | 19,000 | 534,761 | 59,424 | Mar 11 03:55 PM | | HILL CHARLES H | Executive Vice President | Mar 06 | Sale | 28.08 | 21,812 | 612,566 | 74,373 | Mar 08 10:30 AM | | BRANDICOURT OLIVIER | Business Unit President | Mar 06 | Sale | 28.14 | 113,364 | 3,189,585 | 191,076 | Mar 08 10:30 AM | | Dolsten Mikael | President R&D | Mar 06 | Sale | 28.11 | 30,582 | 859,798 | 304,921 | Mar 08 10:30 AM | | SUSMAN SALLY | Executive Vice President | Mar 06 | Sale | 28.13 | 53,196 | 1,496,403 | 198,390 | Mar 08 10:30 AM | | YOUNG JOHN D | Business Unit President | Mar 06 | Sale | 28.13 | 14,713 | 413,877 | 57,520 | Mar 08 10:29 AM | | SUSMAN SALLY | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 77,362 | 1,744,513 | 282,251 | Mar 04 08:00 PM | | YOUNG JOHN D | Business Unit President | Feb 28 | Option Exercise | 22.55 | 26,871 | 605,941 | 63,898 | Mar 04 08:00 PM | | READ IAN C | Chairman & CEO | Feb 28 | Option Exercise | 22.55 | 195,985 | 4,419,462 | 1,139,869 | Mar 04 07:44 PM | | MADDALUNA ANTHONY J | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 19,908 | 448,925 | 75,884 | Mar 04 07:36 PM | | OLSON LAURIE J | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 13,368 | 301,448 | 40,033 | Mar 04 07:36 PM | | HILL CHARLES H | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 21,924 | 494,386 | 91,817 | Mar 04 07:22 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 14,170 | 319,534 | 113,206 | Mar 04 07:22 PM | | DAMELIO FRANK A | Executive Vice President | Feb 28 | Option Exercise | 22.55 | 195,985 | 4,419,462 | 676,472 | Mar 04 06:54 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 28 | Option Exercise | 22.55 | 44,650 | 1,006,858 | 218,306 | Mar 04 06:49 PM | | BRANDICOURT OLIVIER | Business Unit President | Feb 28 | Option Exercise | 22.55 | 47,189 | 1,064,112 | 299,974 | Mar 04 06:40 PM | | YOUNG JOHN D | Business Unit President | Jan 30 | Sale | 27.65 | 26,752 | 739,559 | 36,708 | Feb 01 07:45 AM | | SCHULMAN AMY W | Executive Vice President | Dec 06 | Option Exercise | 17.47 | 100,000 | 1,747,000 | 346,656 | Dec 07 02:36 PM | | SCHULMAN AMY W | Executive Vice President | Dec 06 | Sale | 25.56 | 100,000 | 2,555,930 | 246,656 | Dec 07 02:36 PM | | LANKLER DOUGLAS M | Executive Vice President | Nov 21 | Sale | 24.28 | 11,970 | 290,632 | 90,370 | Nov 21 01:07 PM | | OLSON LAURIE J | Executive Vice President | Sep 13 | Sale | 24.01 | 15,242 | 365,984 | 30,328 | Sep 14 02:13 PM |
|
|
|
|
|
|
